Last reviewed · How we verify
NCT03049709: MEASURE-cBP2
Non-invasive Validation of Non-invasive Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis
trial in Arterial Hypertension in 119 participants. Completed in 30 October 2017.
31 May 2017
Quick facts
| Lead sponsor | Universitätsmedizin Mannheim |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 119 |
| Start date | 1 May 2015 |
| Primary completion | 31 May 2017 |
| Estimated completion | 30 October 2017 |
| Sites | 1 location across Germany |
Conditions studied
- Arterial Hypertension — all drugs for Arterial Hypertension →
- Healthy Control — all drugs for Healthy Control →
- Coronary Heart Disease — all drugs for Coronary Heart Disease →
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
Sponsor
Universitätsmedizin Mannheim — full company profile →
Who can join
18 and older, any sex, with Arterial Hypertension or Healthy Control. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There is growing evidence that central blood pressure is a better predictor of hypertensive end-organ damage and cardiovascular outcome than routine brachial readings. The investigators aimed to evaluate the accuracy of a novel device for the non-invasive determination of central blood pressure based on automated oscillometric radial pulse wave analysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03049709
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Arterial Hypertension
Currently open trials in the same condition.
- NCT06769269 — Hypertension Registry: Study of Primary and Secondary Hypertension Phenotypes, Complications, and Treatment Personalizat · recruiting
- NCT07303556 — Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs · NA · active not recruiting
- NCT06828211 — Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD · NA · active not recruiting
- NCT07049289 — Telemonitoring in Arterial Hypertension · NA · active not recruiting
- NCT06722625 — Telemedical Algorithm-Supported Care for Hypertension · NA · recruiting
Other Universitätsmedizin Mannheim trials
Trials by the same sponsor.
- NCT06416319 — Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct) · NA · recruiting
- NCT04534998 — Robotic-assisted vs. Open Partial Nephrectomy · Phase 2 · unknown
- NCT05575856 — Cardiogenic Shock Registry Mannheim · unknown
- NCT04146701 — Metabolomics and Microbiomics in Cardiovascular Diseases · unknown
- NCT04533633 — German Epicardial Collateral CTO Registry · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03049709 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitätsmedizin Mannheim
- Last refreshed: 27 December 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03049709.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing